Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Earnings of -$0.91 Per Share

Wall Street brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to post earnings of ($0.91) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.99) and the highest estimate coming in at ($0.77). Assembly Biosciences reported earnings per share of ($0.16) in the same quarter last year, which suggests a negative year-over-year growth rate of 468.8%. The business is scheduled to report its next quarterly earnings results on Thursday, March 14th.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.51) to ($3.75). For the next fiscal year, analysts expect that the company will post earnings of ($4.19) per share, with EPS estimates ranging from ($5.35) to ($3.02). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.01) by $0.14. The business had revenue of $4.29 million during the quarter, compared to the consensus estimate of $3.21 million. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%.

ASMB has been the subject of several recent analyst reports. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Monday, October 8th. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Chardan Capital reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Sunday, October 28th. Finally, BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, November 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $52.00.

NASDAQ ASMB opened at $22.00 on Thursday. The firm has a market cap of $606.28 million, a P/E ratio of -9.13 and a beta of 1.42. Assembly Biosciences has a 1 year low of $18.58 and a 1 year high of $67.36.

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its stake in Assembly Biosciences by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 3,289 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 616 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Assembly Biosciences during the 2nd quarter valued at $282,000. Point72 Asset Management L.P. acquired a new position in Assembly Biosciences during the 3rd quarter valued at $407,000. American International Group Inc. raised its stake in Assembly Biosciences by 26.1% during the 3rd quarter. American International Group Inc. now owns 13,946 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 2,886 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Assembly Biosciences during the 3rd quarter valued at $540,000. Hedge funds and other institutional investors own 84.94% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

See Also: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply